GENEVA–(BUSINESS WIRE)–New Product Launches Drive Alcon’s First-Quarter 2026 Growth as Momentum from Unity and Tryptyr Builds
Author: Business Wire
New Product Launches Drive Alcon's First-Quarter 2026 Growth as Momentum from Unity and Tryptyr Builds
GENEVA–(BUSINESS WIRE)–New Product Launches Drive Alcon’s First-Quarter 2026 Growth as Momentum from Unity and Tryptyr Builds
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced that it has …
Epicrispr Biotechnologies and Forge Biologics Announce AAV Development and cGMP Manufacturing Partnership
SAN FRANCISCO & COLUMBUS, Ohio–(BUSINESS WIRE)–Epicrispr Biotechnologies (“Epicrispr”), a clinical-stage company pioneering gene-modulating therapies, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member of the Ajinomoto…
BlinkRx Announces Availability of RYALTRIS® for Convenient Home Delivery Following Glenmark’s Commercial Transition
NEW YORK–(BUSINESS WIRE)–RYALTRIS® nasal spray for seasonal allergic rhinitis is now available through BlinkRx. Transfer your Rx or visit blinkrx.com to learn more.
Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent bus…
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced positive …
Samenvatting: Kubota Vision Inc. sluit een leverings- en licentieovereenkomst met Laboratoires KÔL voor een kandidaat-geneesmiddel tegen de ziekte van Stargardt in het kader van de schrijnende gevallenregeling
CLERMONT-FERRAND, Frankrijk & TOKIO, Japan–(BUSINESS WIRE)–Kubota Vision Inc. (“Kubota Vision”), een volledige dochteronderneming van Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokio, Japan), heeft bekendgemaakt dat het een leverings- en li…
Riassunto: Kubota Vision Inc. firma un accordo di fornitura e licenza con Laboratoires KÔL per un farmaco ad uso compassionevole candidato al trattamento della malattia di Stargardt
CLERMONT-FERRAND, Francia e TOKYO, Giappone–(BUSINESS WIRE)–Kubota Vision Inc. (“Kubota Vision”), azienda interamente controllata da Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Giappone) ha annunciato la firma di un accordo di fornitu…
Kubota Vision Inc. unterzeichnet Liefer- und Lizenzvereinbarung mit Laboratoires KÔL über einen Wirkstoffkandidaten zur Behandlung der Stargardt-Krankheit im Rahmen einer Compassionate-Use-Behandlung
CLERMONT-FERRAND, Frankreich & TOKIO, Japan–(BUSINESS WIRE)–Kubota Vision Inc. („Kubota Vision“), eine hundertprozentige Tochtergesellschaft der Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokio, Japan), gab die Unterzeichnung eines Liefer- …
Resumen: Kubota Vision Inc. firma un acuerdo de suministro y licencia con Laboratoires KÔL para un fármaco candidato para el tratamiento de la enfermedad de Stargardt dentro del programa de uso compasivo
CLERMONT-FERRAND, Francia, y TOKIO, Japón–(BUSINESS WIRE)–Kubota Vision Inc. («Kubota Vision»), una filial de propiedad exclusiva de Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokio, Japón), ha anunciado la firma de un acuerdo de suministro…
STAAR Surgical to Host First Quarter 2026 Earnings Results Call and Webcast on May 13, 2026
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results i…
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use
CLERMONT-FERRAND, France & TOKYO, Japan–(BUSINESS WIRE)– #innovation–Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Ag…
OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical condit…
L’Association canadienne des optométristes souligne le Mois de la santé visuelle avec une campagne en ligne qui invite les Canadiens à se dire : « Faut y voir »
OTTAWA, Ontario–(BUSINESS WIRE)–Vous avez de la difficulté à lire les petits caractères? Il est peut-être temps d’y voir de plus près, comme le rappelle la campagne annuelle de sensibilisation du public de l’Association canadienne des optométristes (…
The Canadian Association of Optometrists celebrates Vision Health Month with online campaign encouraging Canadians to “GetEyeWise”
OTTAWA, Ontario–(BUSINESS WIRE)–Having trouble with the fine print? Perhaps it is time to Get Eyewise, as recommended by the Canadian Association of Optometrists’ (CAO) annual public education campaign. As the national voice of optometry, CAO remains…
Sydnexis to Present New Data from Phase 3 STAR Trial of SYD-101 at ARVO 2026 Annual Meeting
DEL MAR, Calif.–(BUSINESS WIRE)–Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced it will present new data related to a prespecified su…
Alcon Announces Results of 2026 Annual General Meeting
GENEVA–(BUSINESS WIRE)–Alcon Announces Results of 2026 Annual General Meeting
Alcon Announces Results of 2026 Annual General Meeting
GENEVA–(BUSINESS WIRE)–Alcon Announces Results of 2026 Annual General Meeting
Ora Unveils Breakthrough Research in Ophthalmic Clinical Trials, New Blind Canvas Project Stories at ARVO 2026
BOSTON–(BUSINESS WIRE)– #ARVO2026–Leading ophthalmic CRO Ora unveils breakthrough research in ophthalmology clinical trials, new Blind Canvas Project content at ARVO 2026